Connect your AI

Insulet PODD Repayments of Convertible Debt

Repayments of Convertible Debt at other companies

CytokineticsCYTK

$100.63M—

DexComDXCM

$301.88M—

Take-Two Interactive SoftwareTTWO

$0—

Ionis PharmaceuticalsIONS

$66.91M—

Nutanix, Inc.NTNX

$0-100%

Ionis PharmaceuticalsIONS

$66.91M—

Other financials

Income statement

Revenue$761.7M+33.9%

Gross profit$529.0M+29.3%

Operating income$122.1M+37.5%

Net income$91.1M+157%

EPS (diluted)$1.30+160%

Balance sheet

Cash & equivalents$480.4M-62.6%

Total debt$969.7M-45.5%

Total equity$1.3B-2.1%

Total assets$3.0B-15.1%

Cash flow

Operating cash flow$113.8M+78.4%

CapEx$24.3M+97.6%

Free cash flow$89.5M+73.8%

Valuation

Market cap$10.1B-19.9%

Enterprise value$10.59B-19.4%

P/E33.3×+2.0×

P/S3.5×-2.3×

Profitability

Gross margin71%+0.6pp

Operating margin17.5%+2.0pp

Net margin10.4%-7.9pp

FCF margin14.3%+1.1pp

Returns & leverage

Return on equity23%-14.9pp

Debt / equity0.7×-0.6×

Current ratio2.5×-2.0×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfConvertibleDebt.

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's repayments of convertible debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Insulet's repayments of convertible debt?: Insulet (PODD) reported repayments of convertible debt of $0 in Q1 2026.
How has Insulet's repayments of convertible debt changed year-over-year?: Insulet's repayments of convertible debt decreased by 100.0% year-over-year, from $163.9M to $0.